Developer docs
API playgroundTry for free, no card

Search company profiles

Gritstone bio

Full company profile

uuid0004dmc

Namestring
Gritstone bio
Legal namestring
Gritstone bio, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Gritstone bio is a clinical-stage biopharmaceutical company headquartered in Emeryville, California, founded in 2015 and publicly traded on NASDAQ under the ticker GRTS. The company develops immunotherapies for cancer and infectious diseases using two proprietary technology platforms: an antigen discovery platform that identifies tumor-specific neoantigens for personalized oncology treatment, and a self-amplifying mRNA vaccine platform that generates more potent and durable immune responses. Gritstone bio's pipeline spans multiple solid tumor indications (melanoma, lung, pancreatic, gastric, triple-negative breast cancer) and infectious disease applications, including a COVID-19 vaccine candidate developed with CEPI support and intended for the COVAX facility.

The company targets healthcare providers and oncology patients through its cancer vaccine and immunotherapy pipeline, and pursues development partnerships and licensing arrangements with pharmaceutical companies as its primary commercial pathway. Gritstone bio operates without significant product revenue and depends on external capital raises and development partnerships to fund clinical programs; cumulative disclosed funding exceeds $600M across multiple equity, PIPE, debt, and grant rounds. Strategic investors and partners include Frazier Life Sciences Public Fund, Redmile Group, Gilead Sciences, Hercules Capital, Silicon Valley Bank, and CEPI. The company holds 33 AI-related patent filings as of 2025 and reports clinical-trial data showing its mRNA vaccines elicit NeoAg-specific CD8+ T cell responses comprising 1-5% of the circulating repertoire, supporting the technical foundation of its personalized neoantigen approach.

Short descriptiontext

Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen cancer vaccines and self-amplifying mRNA immunotherapies for cancer and infectious diseases, targeting oncology patients and pharmaceutical partners while operating without product revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, neoantigen vaccines, self-amplifying mRNA, personalized oncology, infectious disease vaccines
Industry3 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy and Personalized Neoantigen Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue Stage
TypeSubscription Recurring
Description

Company operates without significant product revenue and remains dependent on external capital raises and development partnerships to fund clinical programs

ad-hoc-news.de
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen-based cancer vaccines and immunotherapies. The company uses a proprietary antigen discovery platform to identify tumor-specific neoantigens and combines this with a self-amplifying mRNA vaccine platform to create individualized oncology treatments and infectious disease vaccine candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • mRNA vaccines generated NeoAg-specific CD8+ T cell responses comprising 1–5% of circulating repertoire in clinical trials
Product overview1 text field

Gritstone bio is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The company's core offering consists of personalized neoantigen-based cancer vaccines and immunotherapies developed using a proprietary antigen discovery platform that identifies tumor-specific neoantigens for individualized oncology treatments. The company also develops infectious disease vaccine candidates leveraging its self-amplifying mRNA vaccine platform. Gritstone bio operates without significant product revenue and remains dependent on external capital raises and development partnerships to fund its clinical programs.

Product and service4 records
1Personalized Neoantigen Cancer Vaccines
2Self-Amplifying mRNA (saRNA) Vaccine Platform
3COVID-19 Vaccine (samRNA)
4Multi-Specific Antibody Immunotherapies
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Moderna is the leading mRNA platform company, with an oncology pipeline that includes personalized neoantigen programs (mRNA-4157). It competes with Gritstone in both mRNA technology and personalized cancer vaccines but at vastly greater scale.

TypeBroad incumbent
Description

BioNTech is a leading mRNA immunotherapy company with FixVac and individualized neoantigen programs (acquired through Neon Therapeutics) that directly overlap with Gritstone's personalized cancer vaccine approach.

TypeDirect peer
Description

CureVac is a clinical-stage mRNA technology company developing both prophylactic vaccines and oncology therapeutics, overlapping with Gritstone's self-amplifying mRNA and cancer immunotherapy programs as a similarly sized direct competitor.

TypeDirect peer
Description

Achilles Therapeutics is a clinical-stage company developing personalized neoantigen immunotherapies for solid tumors, directly comparable to Gritstone's patient-specific cancer vaccine approach in target indication and stage.

TypeEmerging player
Description

Vaccibody (a member of the Nykode Group) develops neoantigen-targeted therapeutic vaccines using a DNA-based vaccine platform, comparable to Gritstone's neoantigen vaccine strategy in oncology indications.

TypeEmerging player
Description

Personalis provides next-generation sequencing-based neoantigen identification and immune profiling for personalized cancer vaccine developers, operating as a complementary/adjacent player to Gritstone's antigen discovery platform.

TypeBroad incumbent
Description

Merck is the maker of Keytruda (pembrolizumab), the dominant checkpoint inhibitor that Gritstone's neoantigen vaccines would likely combine with. Merck also partners with Moderna on mRNA-4157, making it both a potential combination partner and competitive threat.

TypeEmerging player
Description

Genocea developed neoantigen cancer vaccines using its ATLAS platform, directly comparable to Gritstone's antigen discovery and personalized immunotherapy approach in oncology vaccine development.

9Transgene
TypeEmerging player
Description

Transgene develops immunotherapies for solid tumors including therapeutic cancer vaccines using viral vectors, overlapping with Gritstone in the personalized cancer vaccine and immunotherapy category.

TypeBroad incumbent
Description

Roche/Genentech is a leading oncology developer with checkpoint inhibitor franchises and a broad immunotherapy pipeline that intersects with Gritstone's neoantigen vaccine strategy as both a combination partner and competitive incumbent.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gritstone bio

Cancer Immunotherapy and Personalized Neoantigen Vaccinesgritstonebio.com

Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen cancer vaccines and self-amplifying mRNA immunotherapies for cancer and infectious diseases, targeting oncology patients and pharmaceutical partners while operating without product revenue.

What Gritstone bio does

Gritstone bio is a clinical-stage biopharmaceutical company headquartered in Emeryville, California, founded in 2015 and publicly traded on NASDAQ under the ticker GRTS. The company develops immunotherapies for cancer and infectious diseases using two proprietary technology platforms: an antigen discovery platform that identifies tumor-specific neoantigens for personalized oncology treatment, and a self-amplifying mRNA vaccine platform that generates more potent and durable immune responses. Gritstone bio's pipeline spans multiple solid tumor indications (melanoma, lung, pancreatic, gastric, triple-negative breast cancer) and infectious disease applications, including a COVID-19 vaccine candidate developed with CEPI support and intended for the COVAX facility.

The company targets healthcare providers and oncology patients through its cancer vaccine and immunotherapy pipeline, and pursues development partnerships and licensing arrangements with pharmaceutical companies as its primary commercial pathway. Gritstone bio operates without significant product revenue and depends on external capital raises and development partnerships to fund clinical programs; cumulative disclosed funding exceeds $600M across multiple equity, PIPE, debt, and grant rounds. Strategic investors and partners include Frazier Life Sciences Public Fund, Redmile Group, Gilead Sciences, Hercules Capital, Silicon Valley Bank, and CEPI. The company holds 33 AI-related patent filings as of 2025 and reports clinical-trial data showing its mRNA vaccines elicit NeoAg-specific CD8+ T cell responses comprising 1-5% of the circulating repertoire, supporting the technical foundation of its personalized neoantigen approach.

Gritstone bio firmographics

Firmographics
Name
Gritstone bio
Legal name
Gritstone bio, Inc.
Website
https://gritstonebio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen cancer vaccines and self-amplifying mRNA immunotherapies for cancer and infectious diseases, targeting oncology patients and pharmaceutical partners while operating without product revenue.
Ownership category
akta.pro rank

Gritstone bio industry classification

Industry
Product category
Cancer Immunotherapy and Personalized Neoantigen Vaccines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cancer immunotherapy
  • Neoantigen vaccines
  • Self-amplifying mRNA
  • Personalized oncology
  • Infectious disease vaccines

Where Gritstone bio is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Markets served

Gritstone bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pre-Revenue Stage: Company operates without significant product revenue and remains dependent on external capital raises and development partnerships to fund clinical programs

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Gritstone bio product offering

Product offering

Core offering

Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen-based cancer vaccines and immunotherapies. The company uses a proprietary antigen discovery platform to identify tumor-specific neoantigens and combines this with a self-amplifying mRNA vaccine platform to create individualized oncology treatments and infectious disease vaccine candidates.

Product overview

Gritstone bio is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The company's core offering consists of personalized neoantigen-based cancer vaccines and immunotherapies developed using a proprietary antigen discovery platform that identifies tumor-specific neoantigens for individualized oncology treatments. The company also develops infectious disease vaccine candidates leveraging its self-amplifying mRNA vaccine platform. Gritstone bio operates without significant product revenue and remains dependent on external capital raises and development partnerships to fund its clinical programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Neoantigen Cancer Vaccines
  • Self-Amplifying mRNA (saRNA) Vaccine Platform
  • COVID-19 Vaccine (samRNA)
  • Multi-Specific Antibody Immunotherapies

Quantifiable outcome

  • mRNA vaccines generated NeoAg-specific CD8+ T cell responses comprising 1–5% of circulating repertoire in clinical trials

Companies that use Gritstone bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Gritstone bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Gritstone bio partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Gritstone bio competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Moderna is the leading mRNA platform company, with an oncology pipeline that includes personalized neoantigen programs (mRNA-4157). It competes with Gritstone in both mRNA technology and personalized cancer vaccines but at vastly greater scale.
  • BioNTech: BioNTech is a leading mRNA immunotherapy company with FixVac and individualized neoantigen programs (acquired through Neon Therapeutics) that directly overlap with Gritstone's personalized cancer vaccine approach.
  • Merck & Co. Merck is the maker of Keytruda (pembrolizumab), the dominant checkpoint inhibitor that Gritstone's neoantigen vaccines would likely combine with. Merck also partners with Moderna on mRNA-4157, making it both a potential combination partner and competitive threat.
  • Roche / Genentech: Roche/Genentech is a leading oncology developer with checkpoint inhibitor franchises and a broad immunotherapy pipeline that intersects with Gritstone's neoantigen vaccine strategy as both a combination partner and competitive incumbent.

Direct peers

  • CureVac: CureVac is a clinical-stage mRNA technology company developing both prophylactic vaccines and oncology therapeutics, overlapping with Gritstone's self-amplifying mRNA and cancer immunotherapy programs as a similarly sized direct competitor.
  • Achilles Therapeutics: Achilles Therapeutics is a clinical-stage company developing personalized neoantigen immunotherapies for solid tumors, directly comparable to Gritstone's patient-specific cancer vaccine approach in target indication and stage.

Emerging players

  • Vaccibody: Vaccibody (a member of the Nykode Group) develops neoantigen-targeted therapeutic vaccines using a DNA-based vaccine platform, comparable to Gritstone's neoantigen vaccine strategy in oncology indications.
  • Personalis: Personalis provides next-generation sequencing-based neoantigen identification and immune profiling for personalized cancer vaccine developers, operating as a complementary/adjacent player to Gritstone's antigen discovery platform.
  • Genocea Biosciences: Genocea developed neoantigen cancer vaccines using its ATLAS platform, directly comparable to Gritstone's antigen discovery and personalized immunotherapy approach in oncology vaccine development.
  • Transgene: Transgene develops immunotherapies for solid tumors including therapeutic cancer vaccines using viral vectors, overlapping with Gritstone in the personalized cancer vaccine and immunotherapy category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Gritstone bio social profiles

Digital presence

Gritstone bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gritstone bio leadership team

Management profile

Number of profiles

Profiles5 records

Gritstone bio funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gritstone bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gritstone bio

What does Gritstone bio do?

Gritstone bio is a clinical-stage biotechnology company developing personalized neoantigen-based cancer vaccines and immunotherapies. The company uses a proprietary antigen discovery platform to identify tumor-specific neoantigens and combines this with a self-amplifying mRNA vaccine platform to create individualized oncology treatments and infectious disease vaccine candidates.

Is Gritstone bio a public or private company?

Gritstone bio is a public company. It is classified as public and is currently operating.

When was Gritstone bio founded?

Gritstone bio was founded in 2015. It employs 11 to 50 people.

Where is Gritstone bio based?

Gritstone bio is headquartered in Emeryville, United States, in the North America region.

How does Gritstone bio make money?

One revenue line is on record: pre-Revenue Stage.

Who are Gritstone bio's main competitors?

Broad incumbents on record are Moderna, BioNTech, Merck & Co. and Roche / Genentech. Direct peers are CureVac and Achilles Therapeutics. Emerging players are Vaccibody, Personalis, Genocea Biosciences and Transgene.

Does Gritstone bio have an API?

No public API is recorded for Gritstone bio.

What industry is Gritstone bio in?

Gritstone bio's product category is Cancer Immunotherapy and Personalized Neoantigen Vaccines. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Gritstone bio, Inc.Pomerantz LLP announced a proposed class action settlement for purchasers of Gritstone bio securities, with a hearing set for December 4, 2026. The settlement fund totals $6,000,000, and claims must be submitted by November 13, 2026.AD HOC NEWSGritstone bio stock (US3987021022): Vaccine pivot and fresh funding keep hopes aliveGritstone bio, a clinical-stage cancer vaccine and immunotherapy developer, has refocused its pipeline and secured fresh financing after a challenging period on the stock market. The company uses a proprietary antigen discovery platform to identify tumor-specific neoantigens for personalized oncology treatments, while also developing infectious disease vaccine candidates. The firm operates without significant product revenue and remains dependent on external capital raises and development partnerships to fund its clinical programs, positioning it as a high-risk, high-uncertainty small-cap biotech play on Nasdaq.IntuitionLabsAI Patents in Pharma: Ranking the Top 25 Companies (2025)A 2025 industry report analyzing AI patent filings in the pharmaceutical sector found that AI-related patent applications grew at a compound annual rate of approximately 23% from 2020–2022, with leading biotech innovators Gritstone Bio (33 patents) and Guardant Health (26 patents) outpacing traditional pharma giants in filing volume. The United States dominates AI pharmaceutical patenting with roughly 50% of global filings since 2020, followed by China (~17%) and Japan (~12%), as companies across the sector race to build AI-related patent portfolios as a competitive advantage.Business Wire BlogRNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP Therapeutics -The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a 68% CAGR. Over 100 next-generation RNA therapies are in development, with 75% still in discovery or preclinical stages, and investors have poured nearly USD 2.9 billion in the past four years.BenzingaWhy Gritstone Bio (GRTS) Stock Is Down 64% TodayGritstone Bio Inc. voluntarily filed for Chapter 11 bankruptcy restructuring, causing its stock to plummet 64.2% to $0.07. The company intends to use the court-supervised process to preserve value while exploring strategic alternatives and is currently in talks with a potential bidder. Gritstone Bio stated it will continue normal operations, including the development of its GRANITE cancer treatment, during this period.BenzingaDow Falls Over 100 Points; US Inflation Rate Slows To 2.4% In September - XChange Tec (NASDAQ:XHG)U.S. stocks declined on Thursday with the Dow Jones, NASDAQ, and S&P 500 all posting losses, despite the annual inflation rate slowing to 2.4% in September. The broader market drop was accompanied by mixed performance among individual equities, including significant gains for BloomZ Inc. and XChange TEC INC., while Gritstone bio, Inc. plummeted following a Chapter 11 filing.BenzingaPenny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'InsufficieGritstone Bio Inc. revealed interim Phase 2 data from its GRANITE individualized neoantigen-targeting immunotherapy study for frontline microsatellite-stable colorectal cancer, showing a 21% relative risk reduction of progression or death across all treated populations and a 38% reduction in patients with lower disease burden. The company simultaneously announced it engaged Raymond James as financial advisor to evaluate options, while JMP Securities downgraded the stock from Market Outperform to Market Perform citing the data as insufficient to excite investors. GRTS stock fell 57.5% to $0.25 following the announcement.PR NewswireShareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTSLevi & Korsinsky, LLP filed a securities class action lawsuit against Gritstone bio, Inc. on behalf of investors who suffered losses during the period March 9, 2023 to February 29, 2024. The complaint alleges that Gritstone made false statements regarding its ability to launch the Phase 2b CORAL Study for its COVID-19 vaccine and concealed how these delays would impair the company's ability to secure external funding and maintain its cash position. The deadline for investors to request appointment as lead plaintiff was August 6, 2024.PR NewswireGRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud LawsuitLaw Offices of Howard G. Smith announced an opportunity for investors with substantial losses to lead a securities fraud class action lawsuit against Gritstone bio, Inc. (NASDAQ: GRTS), covering the class period March 9, 2023 – February 29, 2024, with a lead plaintiff deadline of August 16, 2024. The complaint alleges that defendants failed to disclose material information, including the company's inability to launch the Phase 2b CORAL Study on schedule and the resulting negative impact on its ability to obtain external funding, balance sheet, and cash position. As a result, the lawsuit claims that positive statements about Gritstone's business, operations, and prospects were materially misleading throughout the class period.